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A 53-years-old woman was diagnosed with lung adenocarcinoma state IV (synchronous
pleural involvement) in April 2009. First-line systemic treatment included six cycles of
Carboplatin, Paclitaxel, and Bevacizumab. Partial response was achieved. Maintenance
therapy with Bevacizumab and Pemetrexed was given from September 2009 to February
2010. No response changes were observed. Immunotherapy was initiated, and then
Pemetrexed was given with the same disease status. Both treatments were well
tolerated. Immunotherapy toxicity included reaction at the site of injection grade 2. At
present, the patient is still on this treatment. Given the poor prognosis of patients with
advanced lung cancer, the combination of both treatments during the stable phase of the
disease may improve progression-free survival.
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CASE PRESENTATION
A 53-years-old woman otherwise previously healthy and a non-
smoker, was diagnosed with lung adenocarcinoma, stage IV T 3
Nx M1a (TNM classification 7th edition) on April 2009.
On March 2009, she presented with functional class III dysp-
nea. A Chest X-ray showed veiling in the left side of the thorax.
CAT scans were performed, and a solid lung mass in the left lower
lobe, associated with pleural effusion and moderate lung collapse
was seen contralateral pleural effusion was also evidenced.
Bronchoscopy showed extrinsic compression of the left lower
lobe bronchus. Pleural biopsy by thoracoscopy, and pleurodesis
with sclerosing agents were performed (talc).
Histological examination of the pleura revealed a prolifera-
tion of epithelial-like atypical cells arranged in glands, nests, and
cords with moderate anisocytosis, anisokaryosis, macronucleoli,
and scattered mitoses. Pleural fluid was positive for neoplastic
cells.
Immunostaining techniques were performed against the fol-
lowing antigens: cytokeratin 7, cytokeratin 20, calrretinina, chro-
mogranin, and TTF, which were positive for cytokeratin 7 and
TTF. These morphological findings are related to moderately dif-
ferentiated adenocarcinoma of pulmonary etiology. Cobas EGFR
test was non-mutated.
First line chemotherapy with carboplatin AUC 6 + pacli-
taxel 200mg/m2 + bevacizumab 15mg/kg every 21 days was
started on May 2009. The patient received six cycles, and this reg-
imen finished in September 2009. Tumor assessment showed
partial response (RECIST). Maintenance therapy with beva-
cizumab 15mg/kg + pemetrexed 500mg/m2 every 21 days
was administered no significant toxicity was associated with
these regimens. Bevacizumab was discontinued in February
2010 and the patient was included in a compassionate program
including Racotumomab. Pemetrexed was administered together
with immunotherapy, and the patient is still on treatment. Partial
response was maintained (Figure 1). As for toxicity associated
with the investigational regimen the patient exhibited a reaction at
the site of injection of the vaccine grade 2. Adverse events related
to pemetrexed were not different from expected, asthenia grade 2.
BACKGROUND
Non-small cell lung cancer (NSCLC) is about 85% of all newly
diagnosed cases of lung cancer, and the leading cause of cancer
related mortality worldwide. Despite some advances in therapy,
the overall prognosis is not encouraging yet; as for all stages of this
devastating disease, less than 20% of patients are alive 5 years after
diagnosis, in the setting of metastatic disease, the median overall
survival (OS) is below 1 year and 4–6 months without treatment
(Fong et al., 2005; Jemal et al., 2010; Winter et al., 2011).
Conventional therapies for NSCLC such as surgery and radio-
therapy are quite effective in the treatment of localized tumors; in
the setting of progressive disease, chemotherapy is still the treat-
ment of choice but, because of toxicity involving normal tissue,
its use is often limited.
The introduction of first-generation chemotherapy (plat-
inum based regimens including paclitaxel, docetaxel, gemcitabine
or vinorelbine) has proven to have only limited activity. The
response rate was 10–15%, with slight improvement in OS with
median survival rates below 11 months, and 31–36% at 1 year
(Winter et al., 2011).
Nowadays, many patients with advanced NSCLC will benefit
from the individualized regimens based on the identifiable molec-
ular characteristics of their tumors. The tumor molecular profile
should help select the appropriate agents for a given patient (Kim
et al., 2012).
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One of the proposed treatment algorithms for advanced
NSCLC in negative or unknown epidermal growth factor recep-
tor (EGFR) mutation or anaplastic lymphoma kinase fusion
protein (EML4-ALK) involves four to six of platinum-based
combinations and currently remains one of the preferred
approaches in the first-line setting (Schiller et al., 2002; Scagliotti
et al., 2008; Gandara et al., 2009).
Second-line therapies have improved OS, but up to 50% of
patients completing first-line treatment become ineligible for fur-
ther treatment, mostly because of significant tumor progression
or rapid decline in performance status (PS) ECOG. Therefore,
many investigators studied the early use of second-line therapy
in the form of maintenance therapy.
Maintenance therapy is defined in the absence of progression
after a first-line platinum-containing regimen. Some investigators
have studied prolonged platinum partner use from the first-line
regimen called “continuation maintenance”; others have studied
the use of a non-cross-resistant agent after induction, which has
been termed “switch maintenance” (Gridelli et al., 2009a). The
approved agents for maintenance therapy include, Pemetrexed,
Docetaxel, Erlotinib, Bevacizumab, and Cetuximab. Although
some randomized studies have shown a small but significant pro-
gression free survival (PFS) and OS benefit for the maintenance
treatment, and guidelines recommend some approved drugs as
first category, this therapy is not universally considered standard.
Moreover, a better understanding of the immune system reg-
ulation is essential, particularly how immune responses against
cancer can be induced, which is mainly mediated by an adap-
tive cellular immune response and finally results in cancer cell
recognition and destruction.
FIGURE 1 | Stable disease after maintenance treatment with
Racotumomab and pemetrexed. (A,C) Computed tomography in March
2010 before treatment. (B,D) Computed tomography in February 2012, last
assessment.
New approaches to improve immune responses and treat
human malignancies have become increasingly refined. These
therapies may prime the immune system to recognize the antigens
expressed in tumor cells, but not in normal tissue thus being able
to destroy these abnormal cells and leave the normal cells intact.
The human immune system uses a complex coordinated set of
cells and signaling molecules to either activate or inhibit immune
responses to endogenous antigens, which are the most commonly
expressed tumor antigens the cellular immune system can use to
specifically target cancer cells.
Some preclinical studies have shown that immunotherapy is
considerably effective against small tumor burdens, but seems
unable to control large masses (Baxevanis et al., 2009). In
advanced stage disease, the pre-existing immunity must have
been insufficient for tumor eradication, although tumor-specific
immune responses have been detected in some cases. This poor
immunological response may include acquired or innate host
tolerance to tumor-associated antigens, tumor development in
an immunoprivileged site, or the expression of tumor-associated
proteins suppressing the activity of cytotoxic T lymphocytes,
among others.
Therapeutic anti-cancer vaccines are intended to cause or
enhance an adaptive immune response to the tumor cells.
Therefore, it is important to identify a specific anti-genic stim-
ulus that will be recognized as immunogenic by the patient’s
immune system, and to create an efficient delivery system to
generate a sufficiently good immune response to the antigen
leading to a clinically relevant result (Thatcher and Heighway,
2010). In other words, vaccines include a tumor antigen source
in order to be immunologically relevant, combined with some
type of “adjuvant” to make these tumor antigens more visible to
the immune system. It was hypothesized that antibody mediated
inflammation could facilitate tumor progression, but high titers
of these antibodies may kill tumor cells (Varki, 2010).
For a long time, lung cancer was not considered an immune-
sensitive malignancy. However, increasing evidence that NSCLC
may evoke specific humoral and cellular anti-tumor immune
responses is available. With more knowledge about the link
between the induced immune response and a resulting objec-
tive clinical response, lung cancer vaccines may be promising in
sequence and/or combination with other anti-tumor treatment
modalities such as chemotherapy to improve vaccination results
(Ma et al., 2004). Both strategies have improved the immune
response in both preclinical and human trials.
A number of promising vaccines based on different types
of antigenic stimuli have been evaluated in clinical stud-
ies; e.g., different immunotherapeutic strategies in lung can-
cer include, active immunotherapy (vaccines, i.e., MAGE),
passive immunotherapy [monoclonal antibodies (mAbs) i.e.,
Ipilimumab] and adoptive T-cell transfer among others (Kelly
et al., 2010).
Gangliosides are a family of sialylated glycolipids that are typi-
cal components of the cell membrane. Some of them have been
identified as tumor associated antigens capable of inducing an
antibody response (Guthmann et al., 2004). For this reason, they
are considered possible targets for cancer management, and have
become the focus of many immunotherapeutic approaches.
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N-acetyl GM3 is one of the most common sialic acid on the cell
surface, abundant in normal serum and one of themost immuno-
logically tolerated members of the family. Also, N- glycolyl-
GM3 (NGcGM3) is relevant for tumor biology due to its high
immunogenicity and expression in several human cancer cells
like melanoma, breast and lung cancer but usually not detected
in normal tissue. Such features make it an excellent target for
immunotherapy (Guthmann et al., 2004; Fernandez et al., 2010;
Machado et al., 2011).
Carbohydrate determinants undergo significant changes dur-
ing malignant transformation. The only structural difference
between N- acetyl- GM3 and N- glycolyl- GM3 is a single
oxygen atom at the C-5 position of NGcGM3, catalyzed by
the cytidinemonophospho-N-acetylneuraminic acid hydroxylase
(CMAH). The absence of NeuGc-neuraminic acid in human cells
is due to the inactivation of the gene by the enzyme respon-
sible for NeuGc biosynthesis. Evidence suggests that its pres-
ence in human cancer might be derived from dietary sources
or from an alternative metabolic pathway (Fernandez et al.,
2010).
One of the approaches to target tumor- associated antigen-
expressing cells is the Anti-idiotype vaccination. Anti-idiotypic
mAbs have been used as cancer vaccines with encouraging results.
This approach comes directly from Jerne’s idiotypic network the-
ory. This theory states that due to the huge diversity potentiality
of the immunoglobulin variable regions, the idiotype repertoire
may mimic the universe of self and foreign epitopes (Machado
et al., 2011). Anti-idiotypic mAbs have proved to be able to mimic
and induce Ag-specific Ab responses, even against non-protein
tumor associated Ags like gangliosides (Figure 2) (Rabu et al.,
2012). These anti–anti-idiotypic and anti-ganglioside mAbs may
bind to tumor gangliosides and mediate complement-dependent
cell lysis or Ab-dependent cell cytotoxicity, inhibit ganglioside-
dependent survival cell functions, or block gangliosides release
from tumor in patient sera, which are known to have immune
suppressive activity (Hernández et al, 2011).
FIGURE 2 | Anti-idiotypic antibodies. An anti-idiotypic antibody (Ab2)
recognizes the hypervariable idiotypic region of a parental antibody (Ab1).
Due to molecular mimicry, an anti-idiotypic antibody may behave like
the original antigen A, in particular when the antibody response (Ab3)
it triggers when used as a vaccine is similar to the antibody
response mounted against the original antigen A (referred to as
anti-anti-Id+/anti-antigen+). Immunizing an animal with antigen A (A) raises
Ab1. Animals immunized with Ab1 will mount a polyclonal antibody
response, amongst which Ab2 may be selected as an anti-idiotypic
antibody (B). Patients or animals vaccinated with Ab2 may mount an Ab3
antibody response, which may both recognize and kill tumor cells
expressing the antigen A (C). mAb, Monoclonal antibody.
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mAbs against gangliosides like NGcGM3 may bind to and
mediate anti-proliferative or cytotoxic activities directly against
target cells through different mechanisms. Because of the genetic
variability and immune evasion capacity of tumors, mAbs with
multiple effector mechanisms may be needed to achieve maximal
anti-tumor effects.
Racotumomab (formerly known as 1E10) is a vaccine that
contains a murine anti-idiotype mAb designed to mimic the
NGcGM3 ganglioside. It is an anti-idiotypic IgG (Ab2-type-
antibody) generated from the murine tumor model immuniza-
tion, the F3II mammary carcinoma (BALB/mice), which reacts
to the IgM mAb (Ab1-type-antibody), named P3 that recognizes
gangliosides as antigens. Both Racotumomab anti-tumoral activ-
ity and preclinical toxicity were analyzed in the murine model
mentioned above and in the B16 melanoma (C57BL/6 mice). The
drug was both safe and effective in these models.
Tumor- specific expression of NGc-containing gangliosides in
some human tumors suggests that the induction of an effec-
tive immune response against these targets might be useful in
patients whose tumors express the antigen. Phase I clinical tri-
als have proven the safety and immunogenicity of Racotumomab
in melanoma, breast cancer and small cell lung cancer patients.
High titer Ab responses to NeuGc-containing gangliosides were
detected in the sera of these patients (van Cruijsen et al., 2009;
Fernandez et al., 2010). NGcGM3 is widely expressed in more
than 90% of NSCLC (van Cruijsen et al., 2009).
In a phase II compassionate—use study, 71 patients with
advanced NSCLC, IIIB, and IV received standard chemoradio-
therapy and then received five biweekly injections of 1mg of
Racotumomab intradermically, other 10 doses at 28 days inter-
vals and continued to be immunized at this same time interval
if they were in good PS ECOG. The vaccine was well toler-
ated; no serious adverse events were reported in this patient
cohort. The most common adverse event was reaction at the
injection site. OS from the time of initial vaccination was 9.93
months (95% CI, 8.61–11.25); 1 year survival rate was 34%, the
median survival time of patients who entered the study with
partial response or disease stabilization and with PS of 1 was
11.5 months (95% CI, 7.97–15.03 months), considered since the
start of vaccination. Those with progressive disease or PS = 2
had a median OS of 6.5 months (95% CI, 4.31–8.69 months).
A statistically significant correlation was observed between anti-
ganglioside response and survival time in a subset of 20 NSCLC
patients from this study. Non-responders (n = 4) had a median
survival time of 6.35 months (95% CI, 4.97–9.67 months),
whereas patients who developed IgG and/or IgM antibodies
against NGcGM3 had a median survival time of 14.26 months
(95% CI, 5.95–17.3 months; P < 0.01) (Kelly et al., 2010;
Guthmann et al., 2004; Hernández et al., 2008; Gridelli et al.,
2009b).
Immune approaches are unlikely to replace conventional can-
cer therapies but, in combination with other therapies, they
may contribute to better results. Moreover, the complex interac-
tions between cancer cells and host elements within the tumor
microenvironment imply that targeting one aspect of tumor biol-
ogy will have clear consequences in other elements involved in
both tumor growth and progression.
It is well known that chemotherapy induces cell death by
apoptosis. Recent evidence suggests that apoptosis may be
highly immunogenic and its immunomodulatory potential is
exerted by a variety of mechanisms. For example, chemother-
apy may condition the tumor microenvironment by modulating
the expression of tumor antigens, accessory molecules of T-cell
activation or inhibition, and molecules involved in antigen pro-
cessing and presentation; furthermore, it may manipulate sys-
temic pathways of immune tolerance and regulation (Emens,
2010).
Some preclinical studies evaluating the combination of vac-
cines with other oncospecific treatments have been published,
providing a rationale for chemoimmunotherapy combinations in
the clinical setting (Fernandez et al., 2010). Preclinical models
using the 3LL Lewis lung carcinoma in C57BL/6 mice as a model
of NSCLC, have shown that the combination of Racotumomab
with chemotherapeutics drugs such as Pemetrexed leads to satis-
factory results (Segatori et al.).
On the other hand, Racotumomab and low-dose
Cyclophosphamide in a mammary carcinoma model signif-
icantly reduced breast carcinoma growth in mice, and that
response was comparable with the co-administration of the
standard high-dose chemotherapy for breast cancer based on
60mg/m (Winter et al., 2011) of Doxorubicin and 600mg/m
(Winter et al., 2011) of Cyclophosphamide, without toxicity signs
(Fuentes et al., 2010).
The Center of Molecular Immunology from Havana, Cuba,
where Racotumomab was developed, conducted a phase I study
to assess the feasibility of combining the vaccine with the stan-
dard first line chemotherapy used in advanced NSCLC. Twenty
patients were included and treated with cisplatin/vinblastine.
The vaccination schedule was administered concomitantly with
chemotherapy and continued beyond progression, until unac-
ceptable toxicity or until the patient decreased PS to grade 3 or
lower. Nineteen patients achieved control disease, median sur-
vival has not been reached and the mean survival was 12.94
months (Macias et al.).
The combination was considered safe and all the patients
developed high antibody responses against Racotumomab dur-
ing the vaccination schedule as well as IgM and IgG antibody
response against NeuGcGm3 antigen as in the standard not
concomitant vaccination schedule used in former clinical trials,
suggesting that chemotherapy does not inhibit vaccine –mediated
immune response (Macias et al.).
DISCUSSION
In advanced NSCLC, systemic chemotherapy and/or localized
irradiation can produce objective responses and palliation of
symptoms; however, these therapies are associated with a modest
improvement in survival despite continuing advances.
To date, maintenance therapy with either a chemotherapeutic
or a molecular target agent after standard first line treatment is
one of the strategies that are continuing under investigation in
several trials. This strategy has shown a substantially longer pro-
gression free survival, but the positive impact on OS is modest.
This approach is associated with more frequent adverse events
with the consequent impairment on quality of life. For these
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reasons, this indication is controversial, and is not considered a
standard of care in many centers.
Tumor vaccines alone in the treatment of solid tumors had
not the expected impact on survival, but its combination with
other treatment modalities such as chemotherapy may increase
its effectiveness. Evidence suggests that irrespective of the potency
of chemotherapy and the specificity achieved with immunother-
apy, neither of these by itself has been enough to eradicate
the disease. Clinical trials have evaluated the combination of
immunotherapy and chemotherapy and have shown synergistic
effect between them that could improve the therapeutic effi-
cacy. Certain chemotherapeutic drugs have immunomodulatory
activities, enhancing the efficacy of tumor cell vaccines and the
immunotherapy response. On the other hand, vaccination may
sensitize the tumor to subsequent chemotherapeutic agents and
induce a dynamic phenomenon in the host immune response,
which it could be modified by concomitant treatment by differ-
ent ways.
The challenge is to combine both conventional treatment and
immunotherapeutic strategies, in order to lower the tumor bur-
den and prepare the host immune system to control minimal
residual disease.
Racotumomab has acceptable safety outcomes and is able to
induce specific humoral and cellular immune responses. These
responses seems to be stronger in those patients with lower tumor
burden, better PS and a good response to previous oncologi-
cal treatments and, in this respect, vaccine therapy might be an
appropriate (van Cruijsen et al., 2009).
Regarding Pemetrexed maintenance therapy, the first analy-
sis has shown that Pemetrexed improves median progression-free
survival vs. placebo (4.1 months from randomization vs. 2.8
months respectively). This analysis shows an improvement on
medianOS also (13.9months from randomization vs. 11months)
(Paz-Ares et al., 2012a,b).
Here, we presented a case report of an advanced NSCLC
patient who seems to have been benefited from maintenance
therapy and/or immunotherapy. PFS and OS are higher than
expected. Toxicities were not higher than described with these
agents when used alone.
CONCLUDING REMARKS
Given the results presented in this case report we consider that
the combination of chemotherapy and immunotherapy deserves
further investigation.
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